KISSEI's History

Aug. 1946

Founded as Tachibana Seikagaku Institute Co., Ltd.

May 1947

Corporate name changed to Kissei Yakuhin Kogyo Co., Ltd.

Dec. 1961

GASCON, a gastrointestinal anti-gas agent, launched.

Oct. 1964

Corporate name changed to Kissei Pharmaceutical Co., Ltd. 
Head Office and factories constructed at present location.

May 1969

Central Research Laboratories constructed.

Apr. 1973

Central Research Laboratories expanded.

Jul. 1980

Manufacturing Plant constructed.

Aug. 1982

RIZABEN, a drug for the treatment of allergic diseases, launched.

Jun. 1985

Safety Research Laboratories constructed.

May 1986

Manufacturing Plant expanded.

Aug. 1986

UTEMERIN, a drug for threatened abortion and preterm labor,
launched.

Apr. 1988

XANBON, a drug for cerebral circulation improvement, launched.

Dec. 1988

Company listed on the Second Section of the Tokyo Stock Exchange.

Apr. 1990

Foodstuff Business Unit established.
Jellix, low energy jelly, launched.

Nov. 1990

Central Research Laboratories moved.

Apr. 1991

BEZATOL, a drug for the treatment of hyperlipidemia, launched.

Sep. 1991

Company listed on the First Section of the Tokyo Stock Exchange.

Dec. 1991

Kissei Information Center constructed.

Mar. 1992

Genta Soba, protein controlled soba noodles, launched.

May 1992

FRAGMIN, an anti-coagulant, launched.

Jun. 1992

DOMENAN, a drug for the treatment of bronchial asthma, launched.

Aug. 1992

Wholly owned Nagoya Branch building constructed.

May 1993

Matsumoto Third Drug Manufacturing Plant constructed.

Oct. 1994

Shiojiri Plant constructed.

Jul. 1995

Tokyo Head Office established.

Nov. 1995

Wholly owned Sendai Branch building constructed.
First Quality Control Laboratory constructed.

Dec. 1995

RIZABEN Eye Drops, a drug for the treatment of allergic conjunctivitis,
launched.

Aug. 1996

50th anniversary of the company's founding.

Sep. 1996

Pharmaceutical Laboratories constructed.

Dec. 1996

History of Kissei's 50 Years compiled.

Mar. 1997

Tokyo Head Office(Koishikawa) established.

Oct. 1997

Kissei U.S.A., Inc. subsidiary established.

Dec. 1997

Wholly owned Sapporo Branch building constructed.

May 1999

Safety Research Laboratories expanded.

Dec. 1999

Environmental directive established.

Oct. 2000

ZOLADEX 1.8mg Depot, a drug for the treatment of endometriosis,
launched.

May 2001

Nutritional Business Center constructed.

Aug. 2001

FULSTAN, an active vitamin D3 preparation, launched.

Apr. 2004

U.S.-based companies reorganized, Kissei America, Inc. established.

May 2004

GLUFAST, a drug for the treatment of type 2 diabetes, launched.

Mar. 2005

Yume Series, protein controlled foods, launched.
Macton Series, energy supply foods, launched.

Sep. 2005

SALAGEN, a drug for the treatment of xerostomia, launched.

May 2006

URIEF, a drug for the treatment of dysuria associated with benign
prostatic hyperplasia, launched.

Feb. 2007

Central Research Laboratories expanded.

Apr. 2007

Joetsu Chemical Laboratories constructed.

Dec. 2008

New through-king i , viscosity modifier, launched.

Apr. 2009

Silodosin (brand name in Japan : URIEF ), a drug for the treatment of dysuria
associated with benign prostatic hyperplasia, launched in the US.

Feb. 2010

Yume no shokutaku, assorted protein controlled frozen meal, launched.

Apr. 2010

New main building of head office constructed.

May 2010

EPOETIN ALFA BS Injection, a drug for the treatment of renal anemia, launched.

Mar. 2011

Genta Soy Sauce, protein controlled, low-salt soy sauce, launched.

Jul. 2011

GLUBES, a drug for the treatment of type 2 diabetes,launched.

Aug. 2012

Yume Bakery, protein controlled bread, launched.

Sep. 2013

Safety Research Laboratories expanded.

Apr. 2014

SAVENE, a drug for the treatment of anthracycline extravasation, launched.

Mar. 2015

Safety Research Laboratories received full accreditation from AAALAC International.

Nov. 2015

P-TOL, a drug for the treatment of hyperphosphatemia, launched.

Dec. 2015

Yume no shokutaku, 4 products of protein controlled frozen lunch, launched.

Jan. 2016

URIEF OD Tab. (Orally Disintegrating Tablets), a drug for the treatment of
dysuria associated with benign prostatic hyperplasia, launched.

Feb. 2016

Nomiyasui, hydration jelly drink, launched.

Jun. 2016

GLUFAST OD Tab. (Orally Disintegrating Tablets), a drug for the treatment of
type 2 diabetes, launched.

Aug. 2016

Enepaku jelly, energy and protein supply dessert, launched.

Dec. 2017

RECTABUL, a drug for the treatment of Ulcerative Colitis, launched.

Nov. 2018

BEOVA, a drug for the treatment of overactive bladder, launched.
P-TOL Granules, a drug for the treatment of hyperphosphatemia, launched.

Jun. 2019

GLUBES OD Tab. (Orally Disintegrating Tablets), a drug for the treatment of type 2 diabetes, launched.

Oct. 2019

Okayu carethrough, viscosity modifier for rice porridge, launched.

Nov. 2019

DARBEPOETIN ALFA BS Injection, a drug for the treatment of renal anemia, launched.

Apr. 2020

MARIZEV, a drug for the treatment of type 2 diabetes, distribution started.

Apr. 2022

Company listed on the Prime Market of the Tokyo Stock Exchange.

May 2022

CAROGRA, a drug for the treatment of Ulcerative Colitis, launched.

Jun. 2022

TAVNEOS, a drug for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), launched.

Apr. 2023

TAVALISSE, a drug for the treatment of chronic idiopathic thrombocy to penic purpura (ITP), launched.

Dec. 2023

KORSUVA, a drug for the treatment of pruritus in patients undergoing hemodialysis, launched.